Safety Shot licenses Jupiter Wellness assets to Elite Health; to dividend 40% of post-IPO shares

BONK, INC.

Received 4M shares of Elite Health common stock; license to convert to purchase upon Elite's IPO.
Elite Health plans IPO by Q3 2024; upon completion, Safety Shot to receive $1 and dividend 40% of Elite shares.
Safety Shot's beverage assets (Safety Shot, NoStingz) are not included; company focuses on functional beverage.
Elite Health, FDA-registered manufacturer, expects to launch MIDAS SaaS platform for manufacturing management.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

BONK, INC. entered into License and Purchase Agreement with Elite Health Partners Inc. valued at 4,000,000 shares of Licensee Common Stock; option to purchase Legacy Assets for $1.00 upon IPO compl (effective 2024-02-21).

Action: entry
Agreement: license
Counterparty: Elite Health Partners Inc.
Value: 4,000,000 shares of Licensee Common Stock; option to purchase Legacy Assets for $1.00 upon IPO compl
Effective: 2024-02-21

Exact text from the filing

On February 21, 2024, Safety Shot Inc. (the “ Company ”) entered into a License and Purchase Agreement (the “ Purchase Agreement ”), with Elite Health Partners Inc., a Delaware corporation (“ Licensee ”), pursuant to which the Company granted to Licensee a license to use assets related to the development and sale of various over-the-counter health and wellness products owned by the Company (the “ Legacy Assets ”) and the option to purchase the Legacy Assets upon fulfillment by Licensee of certain conditions set forth in the Purchase Agreement.

View on SEC.gov

380 material agreements filed in the last 30 days. Browse all material agreements →

BONK, INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-007504

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.